Crazy Rich Hong Kong | Science Park, Biotech and the Deep-Tech Innovation Economy begins with the moment a scientific idea stops being a paper and starts becoming something the world can actually use.
Search for “Hong Kong Science Park”, “Hong Kong biotech”, “Hong Kong innovation”, “Hong Kong startups”, “Hong Kong AI” or “Hong Kong life science” and Hong Kong Science and Technology Parks Corporation sits near the centre of the map.
By May 2026, HKSTP reported more than 2,400 innovation and technology companies across its ecosystem, a working population above 26,000, more than 17,000 R&D practitioners, and over HK$170 billion raised by Park companies since fiscal 2018. Its life-and-health-technology ecosystem alone now contains more than 400 companies.
The Crazy Rich story is not glass offices or startup buzzwords. It is the construction of a pipeline that can move an idea from laboratory to prototype, clinical trial, manufacturing, investment and market.
Did You Know? Deep Tech Is Expensive Because Reality Must Cooperate
A software idea can sometimes be tested with a laptop.
A new drug, robot, semiconductor process or medical device may require laboratories, specialised equipment, regulatory approval, manufacturing expertise and years of testing.
That is why deep-tech ecosystems need more than entrepreneurial energy.
They need infrastructure.
Hong Kong Science Park Is a Cluster, Not Just a Campus
Science Park brings companies, laboratories, research organisations and support services into one physical environment.
The objective is proximity.
When an AI company, biotech researcher, investor and university team can meet without crossing a continent, collaboration becomes easier.
Innovation often depends less on one genius and more on how quickly different kinds of expertise can find one another.
More Than 2,400 I&T Companies
HKSTP’s company base spans several technology fields:
- artificial intelligence and data;
- life and health technology;
- electronics and robotics;
- microelectronics;
- advanced manufacturing;
- sustainable materials; and
- digital transformation.
This diversity matters because breakthroughs increasingly happen between fields.
AI enters drug discovery. Robotics enters healthcare. Materials science enters electronics. Computing changes biology.
The boundaries between industries are becoming thinner.
Why 17,000 R&D Practitioners Matter
Buildings do not innovate.
People do.
A dense concentration of researchers, engineers and technical specialists creates a labour market in which companies can hire, collaborate and exchange knowledge.
That human density is one of the hardest assets for another city to copy quickly.
The HK$170 Billion Capital Pipeline
HKSTP says its companies have raised more than HK$170 billion since fiscal 2018.
Capital matters because deep technology often needs years of development before revenue becomes large.
Investors are effectively financing uncertainty.
The better the surrounding technical and regulatory ecosystem, the more intelligently that uncertainty can be evaluated.
Hong Kong’s Life and Health Technology Cluster
HKSTP’s life-and-health ecosystem includes more than 400 companies working across biotechnology, diagnostics, therapeutics, medical devices and digital health.
The ambition is to support the full journey from bench to bedside.
That phrase matters.
A discovery becomes medically meaningful only when it can survive testing, regulation, manufacturing and real-world use.
Biotech Is a Translation Problem
Scientists may understand a disease mechanism without having a medicine.
The gap between discovery and treatment is called translation.
Bridging it requires:
- preclinical research;
- clinical trials;
- manufacturing;
- quality systems;
- regulatory strategy;
- capital; and
- commercial partnerships.
Science Park’s value is partly its attempt to make those bridges easier to cross.
Hong Kong as the World’s Second-Largest Biotech Fundraising Hub
HKSTP describes Hong Kong as the world’s second-largest biotech fundraising hub.
This reflects the connection between science and capital markets.
HKEX’s listing framework for pre-revenue biotech companies gives research-intensive firms another possible financing route.
A laboratory becomes more powerful when the capital market understands how to finance laboratories.
AI Drug Discovery Changes the Search Space
Artificial intelligence can help researchers explore chemical structures, biological targets and potential drug candidates more efficiently.
That does not make experiments unnecessary.
It changes where experiments begin.
AI can narrow the search space before expensive physical testing starts.
This is words-to-technology and data-to-technology interface design at scientific scale.
The Metis TechBio Listing
In May 2026, HKSTP highlighted the listing of Metis TechBio on HKEX as the world’s first publicly listed AI drug-delivery company.
The significance is not one company alone.
It demonstrates a route from technology platform to public capital market.
For an ecosystem, visible exits create confidence that the pipeline can complete.
Cell and Gene Therapy Requires Manufacturing, Not Just Research
In July 2026, Science Park announced Hong Kong’s first PIC/S GMP-certified facility for manufacturing certain stem-cell products for clinical trials.
That milestone matters because advanced therapies cannot move from research into patients without controlled manufacturing.
The glamorous phrase is “breakthrough medicine.”
The practical phrase is “quality system.”
Clinical Trials Are a Bridge Between Science and Medicine
Clinical trials test whether potential therapies are safe and effective in people.
They require hospitals, doctors, patients, data systems, ethics review and regulatory oversight.
Hong Kong’s dense healthcare and university network gives the city an unusual opportunity to connect research institutions with clinical settings.
The science becomes valuable when it can meet evidence.
AI Is a Second Major Pillar
HKSTP said in 2026 that it was home to more than 500 AI ventures and over 5,000 AI professionals.
AI is not one industry.
It is becoming a general-purpose capability that enters finance, healthcare, manufacturing, logistics, robotics and public services.
This makes an AI cluster valuable because it can improve many other clusters.
From Science Park to InnoParks
HKSTP also operates InnoParks in Tai Po, Yuen Long and Tseung Kwan O to support advanced manufacturing and “new industrialisation”.
This solves a common innovation problem.
A successful prototype eventually needs to be manufactured.
If manufacturing capability is too far away, commercialisation slows down.
The laboratory and factory need a bridge.
San Tin Technopole and the Next Expansion
Hong Kong is developing San Tin Technopole as a major future innovation hub near Shenzhen.
HKSTP is planning the INNOPOLE component within the area.
The location is strategically interesting because it moves Hong Kong’s innovation geography closer to Shenzhen’s technology ecosystem.
The boundary becomes a connection point rather than only a separation.
Why University Spin-Offs Matter
Universities generate research, but spin-offs create vehicles capable of hiring staff, raising investment and selling products.
In 2026, HKSTP’s largest-ever BIO International Convention delegation included companies and university spin-offs linked with HKU, CUHK, HKUST, PolyU and CityUHK.
This shows the mechanism clearly:
university → invention → spin-off → science park → investment → market.
Singapore and Hong Kong: Two Research-Cluster Models
Singapore’s one-north and Biopolis integrate research institutes, universities, hospitals and global companies.
Hong Kong Science Park connects universities, start-ups, industry, HKEX and the Greater Bay Area.
Both demonstrate the same civilisational principle: knowledge compounds faster when the institutions around it are connected.
What Students Can Learn from Science Park
Science
A discovery becomes useful only after testing, replication and translation.
Mathematics
AI, clinical trials and engineering depend on statistics, optimisation and modelling.
Economics
Deep-tech companies need patient capital because development can precede revenue by years.
Engineering
Prototypes must eventually survive real manufacturing constraints.
Education
Advanced technology requires people capable of understanding and operating increasingly complex systems.
Ten Vocabulary Words for Deep Tech
1. R&D
Research and development: systematic work aimed at creating new knowledge, products or processes.
2. Deep tech
Technology based on substantial scientific or engineering advances that are difficult to reproduce quickly.
3. Translation
The process of turning research discoveries into practical applications.
4. Clinical trial
A structured study evaluating a medical intervention in human participants.
5. GMP
Good Manufacturing Practice, quality rules governing consistent and controlled production.
6. Incubator
An organisation or programme that helps early-stage companies develop.
7. Spin-off
A company created from research or technology developed within another institution.
8. Commercialisation
Turning technology or research into products and services used in the market.
9. Venture capital
Investment capital provided to high-growth companies with significant risk and potential return.
10. Ecosystem
A network of connected organisations, people and infrastructure that reinforce one another.
Frequently Asked Questions
How many companies are in the HKSTP ecosystem?
More than 2,400 innovation and technology companies as of May 2026.
How many R&D practitioners are there?
More than 17,000 across the HKSTP ecosystem, according to May 2026 figures.
How much capital have Park companies raised?
More than HK$170 billion since fiscal 2018.
How many life and health technology companies are there?
HKSTP’s current life-and-health-technology page reports more than 400 Park companies.
Does Science Park only support biotech?
No. Its ecosystem also covers AI, electronics, robotics, advanced manufacturing, digital transformation and sustainable technologies.
Why does Science Park matter to Hong Kong?
It connects research, talent, capital, industry and infrastructure so ideas have a clearer path toward commercialisation.
Helpful Reading Across the Hong Kong and Singapore Graph
- Crazy Rich Hong Kong | Universities, Research and the Global Talent Economy
- Crazy Rich Hong Kong | Cyberport, FinTech and the Digital Assets Economy
- Crazy Rich Singapore | one-north, Biopolis and the Research Cluster Economy
- Crazy Rich Singapore | Biopharmaceutical Manufacturing and Life Sciences
References and Current Sources
- Hong Kong Science and Technology Parks Corporation, About HKSTP, data as of May 2026.
- HKSTP, Life and Health Technology.
- HKSTP, BIO International Convention 2026 Hong Kong Delegation.
- HKSTP, Cell and Gene Therapy Showcase 2026.
Crazy Rich Hong Kong Builds the Bridge from Idea to Reality
Innovation is easy to celebrate after it works.
The difficult part is everything before that moment.
Years of research. Failed experiments. Regulatory review. Manufacturing. Capital. Talent.
Did you know? The richest innovation systems are not those that produce the most ideas.
They are the ones that give good ideas enough bridges to survive.